AMARIN CORPORATION PLC - AMERICAN DEPOSITARY SHARE

Amarin Chairman & CEO Issue Letter to Shareholders

22 Jan 2024 07:30:00 By Nasdaq GlobeNewswire

Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024

10 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference

11 Dec 2023 08:00:00 By Nasdaq GlobeNewswire

Amarin Reports Third Quarter 2023 Financial Results

01 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer

31 Oct 2023 12:00:00 By Nasdaq GlobeNewswire

Latest Research Evaluating VASCEPA®/VAZKEPA® (icosapent ethyl) and Subgroups from the REDUCE-IT Landmark Outcomes Trial to be Presented at the American Heart Association (AHA) Scientific Sessions 2023

26 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

 Amarin to Report Third Quarter 2023 Financial Results and Host Conference Call on November 1, 2023

19 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Amarin to Present at the 2023 Cantor Global Healthcare Conference

12 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

Amarin Provides Pricing & Reimbursement Updates for VAZKEPA (icosapent ethyl) in The Netherlands and Italy

09 Aug 2023 16:05:01 By Nasdaq GlobeNewswire

Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in Israel

08 Aug 2023 07:00:01 By Nasdaq GlobeNewswire

Scottish Medicines Consortium Accepts VAZKEPA® (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland(1)

07 Aug 2023 07:00:40 By Nasdaq GlobeNewswire

Amarin Reports Second Quarter 2023 Financial Results

02 Aug 2023 07:11:03 By Nasdaq GlobeNewswire

Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea

31 Jul 2023 08:00:01 By Nasdaq GlobeNewswire

Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress

26 Jul 2023 08:00:01 By Nasdaq GlobeNewswire

Amarin Receives Positive Recommendation from Spanish Drug Pricing Committee for National Reimbursement of VAZKEPA® (icosapent ethyl) in Spain

25 Jul 2023 16:05:00 By Nasdaq GlobeNewswire

Amarin Board of Directors Announces Executive Compensation Program for New President and CEO Patrick Holt

20 Jul 2023 08:00:00 By Nasdaq GlobeNewswire

Amarin Appoints Patrick Holt as President and Chief Executive Officer

18 Jul 2023 16:16:00 By Nasdaq GlobeNewswire

Amarin Implements Organizational Restructuring to Strengthen the Company While Driving Patient Access to VASCEPA®/VAZKEPA® Globally

18 Jul 2023 16:15:00 By Nasdaq GlobeNewswire

Amarin Announces Vascepa® (Icosapent Ethyl) Approved to Reduce Cardiovascular Risk in the Kingdom of Saudi Arabia (KSA)

21 Jun 2023 09:00:54 By Nasdaq GlobeNewswire

Amarin to Present at Two Upcoming Investor Conferences

01 Jun 2023 16:30:00 By Nasdaq GlobeNewswire